ABBV-706 + Chemotherapy for Advanced Solid Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, ABBV-706, alone or with other drugs to treat aggressive cancers like small cell lung cancer and certain brain tumors. It aims to find the best dose and check its safety and effectiveness. The study involves periodic hospital visits and medical tests over several years.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What makes the drug ABBV-706 + Chemotherapy unique for treating advanced solid cancers?
What data supports the effectiveness of the drug ABBV-706 + Chemotherapy for Advanced Solid Cancers?
The research highlights that antibody-drug conjugates (ADCs), like ABBV-706, have shown effectiveness in treating some solid and blood cancers. Additionally, combining platinum-based drugs like cisplatin and carboplatin with other cancer treatments can enhance their effectiveness and reduce resistance.36789
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
Adults with advanced solid tumors, including specific types of lung cancer and high-grade brain or neuroendocrine cancers that have worsened despite standard treatments. Participants must be in good physical condition (ECOG 0-1), have acceptable heart function, and measurable disease. Those with certain lung conditions or previous treatment with similar drugs are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
ABBV-706 is intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose is determined
Dose Optimization and Expansion
Participants receive varying doses of ABBV-706 in a randomized manner to determine the recommended Phase 2 dose
Combination Treatment
Participants receive ABBV-706 in combination with budigalimab, carboplatin, or cisplatin
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABBV-706
- Budigalimab
- Carboplatin
- Cisplatin
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois